2026-08-10 · TIRZEPATIDE · TopGLP1Providers Data Desk

How to vet a tirzepatide telehealth provider before your card is charged

A legitimate compounded tirzepatide program in 2026 will pass nine checks: it names its pharmacies (503A or FDA-registered 503B), screens you like a clinic rather than a checkout, states the all-in price at every dose in writing, discloses the full upfront charge, publishes cancellation and refund terms you can actually execute, lists the states it serves, uses licensed prescribers you can verify, never ships without a valid patient-specific prescription, and never sells "research use only" product. Fail any one and keep your money.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

Pharmacy transparency is the sharpest filter in the index. Of the 32 compounded programs we track, only a minority name their fulfillment pharmacies at all. NexLife↗ publishes a six-pharmacy 503A/503B network and states it does not compound medication itself; Mochi operates its own compounding facility. Most of the rest say "our partner pharmacy" and stop. An unnamed pharmacy cannot be checked against its state board, its inspection history, or the FDA's registration lists — which is the entire point of naming it. Treat "we work with US pharmacies" the way you would treat a restaurant that will not say where the kitchen is.

Screening should feel slightly inconvenient. Since compounding now requires documented, patient-specific clinical need, a real program asks about your history, medications, contraindications, and goals, and a real prescriber can decline you. A questionnaire that cannot fail anyone is not screening; it is paperwork wrapped around a sale. Video-visit programs (Mochi) and async programs with substantive intake both can be legitimate — the tell is whether "no" is a possible answer.

Price honesty has three tests covered at length elsewhere on this site: the maintenance-dose price in writing (flat vs tiered), mandatory memberships folded into the quoted total, and prepaid terms labeled as prepaid with refund terms attached. A program that flunks pricing honesty usually flunks quietly elsewhere too; in our data, the programs with unpublished maintenance prices are disproportionately the ones with unpublished pharmacies and unpublished state lists.

Then verify independently. Look up the prescribing clinician's license in your state's database; check the named pharmacy with its state board of pharmacy and, for 503Bs, the FDA's outsourcing-facility list; search the company against FDA warning letters; read the cancellation clause before, not after, prepaying. Ten minutes of this work filters out most of what goes wrong in this category. Our provider pages pre-load what each program publishes — pharmacy type, states, cancellation language, evidence status — so you can see who makes verification easy and who makes it impossible, which is itself the answer.

Vetting guidance, not an endorsement of any program; clinical appropriateness is a prescriber conversation.